SEC ownership of Passage BIO, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001787297.

Holder evidence

50

Lead holder

Lynx1 Capital Management LP

13D/G signal

Lynx1 Capital Management LP

Latest evidence

19 May 2026

Top shareholders Insider holders Latest transactions
Ownership snapshot 4 facts
SEC evidence mix
13F, 13D/G, and 3/4/5
Lead holder
Lynx1 Capital Management LP
Latest large-stake holder
Lynx1 Capital Management LP
Latest evidence date
19 May 2026
Issuer identity 3 facts
CIK
0001787297
Symbol
PASG on Nasdaq
Location
Philadelphia, PA

Ownership snapshot

Top shareholders of Passage BIO, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Lead holder
Lynx1 Capital Management LP
13D/G signal
Lynx1 Capital Management LP
Evidence rows
50
Latest as of
19 May 2026
13F 13D/G 3/4/5 Lead comparable stake: 20% 13D/G row: Lynx1 Capital Management LP Showing 1-8 of 50 holder rows.
Holder Evidence Ownership % Position 12M Net Δ As of
Lynx1 Capital Management LP
13F 13D/G 3/4/5
Company · 10%+ Owner
13F 13D/G 3/4/5
20%
from 13D/G
$4,896,076
623,704 shares
 — 31 Mar 2026
Erste Asset Management GmbH
13D/G 13F
Company
13D/G 13F
4.4%
$810,414
2,455,800 shares
 -$166,650 31 Mar 2024
ORBIMED ADVISORS LLC
3/4/5 13D/G
10%+ Owner
3/4/5 13D/G
4.2%
from 13D/G
$2,001,893
6,066,343 shares
 -$197,239 24 Jun 2025
Thomas Woiwode
3/4/5
Director, 10%+ Owner
3/4/5
—
class O/S missing
—
24,000 shares
 — 25 May 2023
Vestal Point Capital, LP
13F
Company
13F
—
class O/S missing
$2,394,250
305,000 shares
 — 31 Mar 2026
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
class O/S missing
$1,048,854
133,612 shares
 — 31 Mar 2026
Eversept Partners, LP
13F
Company
13F
—
class O/S missing
$1,032,911
131,581 shares
 — 31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC
13F
Company
13F
—
class O/S missing
$894,617
113,964 shares
 — 31 Mar 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$26,496.

Buys
$223,735
Insiders: 1
Sells
$197,239
Insiders: 1
Net
+$26,496
Shares: -551,649
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 32,008 Shares: 583,657
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 32,008 0 $223,735 $0 +$223,735
9-12 0 583,657 $0 $197,239 -$197,239

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-20 of 25 reporting-owner rows connected to Passage BIO, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
25
Lead holder
Lynx1 Capital Management LP
Net 12M change
+$26,496
Latest report
19 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Lynx1 Capital Management LP 10%+ Owner $4,359,379 +$223,735 +5.4% Filing P/S 11 Sep 2025
ORBIMED ADVISORS LLC 10%+ Owner $2,001,893 -$197,239 -9% Filing P/S 24 Jun 2025
Jill M. Quigley Chief Operating Officer $338,849 Mixed 08 Dec 2021
William Chou PRESIDENT AND CEO, Director $58,650 Mixed 16 Mar 2026
Mark S. Forman Chief Medical Officer $56,272 Mixed 15 Mar 2024
Alexandros Fotopoulos Chief Technical Officer $48,861 Mixed 15 Jun 2023
Kathleen Borthwick Cfo $48,563 Mixed 16 Mar 2026
Simona King Chief Financial Officer $21,835 Mixed 28 Jul 2023
Monika Maria Toernsen Chief Commercial Officer $16,670 Mixed 15 Sep 2022
Richard Steven Morris Chief Financial Officer $4,963 Mixed 21 May 2021
Eliseo Oreste Salinas Chief Res. & Develop Officer Mixed 10 Feb 2022
Athena Countouriotis Director Mixed 19 May 2026
Maxine Gowen Director Mixed 19 May 2026
Brian Burkavage Controller Mixed 30 May 2021
Derrell Porter Director Mixed 19 May 2026
Sandip Kapadia Director Mixed 19 May 2026
Thomas Richard Kassberg Director Mixed 19 May 2026
Michael E. Kamarck Director Mixed 25 May 2023
Bruce A. Goldsmith CEO and President, Director Mixed 27 May 2022
Thomas Woiwode Director, 10%+ Owner Mixed 25 May 2023

Recent insider transactions for Passage BIO, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Reported value Reported price Shares Shares owned Date Ownership
Dolan Sondhi PASG Director Stock Option (right to buy) Award 10,539 10,539 19 May 2026 Direct
Derrell Porter PASG Director Stock Option (right to buy) Award 10,539 10,539 19 May 2026 Direct
Thomas Richard Kassberg PASG Director Stock Option (right to buy) Award 10,539 10,539 19 May 2026 Direct
Sandip Kapadia PASG Director Stock Option (right to buy) Award 10,539 10,539 19 May 2026 Direct
Maxine Gowen PASG Director Stock Option (right to buy) Award 10,539 10,539 19 May 2026 Direct
Athena Countouriotis PASG Director Stock Option (right to buy) Award 10,539 10,539 19 May 2026 Direct
Kathleen Borthwick PASG Employee Stock Option (right to buy) Award 15,610 15,610 16 Mar 2026 Direct
William Chou PASG Employee Stock Option (right to buy) Award 58,000 58,000 16 Mar 2026 Direct
William Chou PASG Common Stock Sale -38.4% -4,076 6,524 08 Jan 2026 Direct
William Chou PASG Common Stock Options Exercise 1666.7% 10,000 10,600 08 Jan 2026 Direct
William Chou PASG Restricted Stock Unit Options Exercise -50% -10,000 10,000 08 Jan 2026 Direct
Kathleen Borthwick PASG Common Stock Sale -27.6% -2,062 5,402 08 Jan 2026 Direct
Kathleen Borthwick PASG Common Stock Options Exercise 202.9% 5,000 7,464 08 Jan 2026 Direct
Kathleen Borthwick PASG Restricted Stock Unit Options Exercise -50% -5,000 5,000 08 Jan 2026 Direct
Lynx1 Capital Management LP PASG Common Stock Purchase 1.95% $83,175 $6.99 11,900 623,704 15 Sep 2025 See footnote
Lynx1 Capital Management LP PASG Common Stock Purchase 3.34% $138,299 $6.99 19,783 611,804 12 Sep 2025 See footnote
Lynx1 Capital Management LP PASG Common stock, $0.0001 par value per share (Common Stock) Purchase 0.05% $2,261 $6.96 325 592,021 11 Sep 2025 See footnote
Lynx1 Capital Management LP PASG Common Stock Purchase 12.6% 66,423 591,696 24 Jul 2025 See footnote
Lynx1 Capital Management LP PASG Common Stock Purchase 10.4% 49,302 525,273 23 Jul 2025 See footnote
Lynx1 Capital Management LP PASG Common stock, $0.0001 par value per share ("Common Stock") Purchase 2.84% 13,123 475,971 22 Jul 2025 See footnote
Orbimed Advisors Llc PASG Common Stock Sale -3.4% $70,375 $0.3300 -213,257 6,066,343 26 Jun 2025 See footnotes
Orbimed Advisors Llc PASG Common Stock Sale -2.16% $45,804 $0.3300 -138,800 6,279,600 25 Jun 2025 See footnotes
Orbimed Advisors Llc PASG Common Stock Sale -3.48% $81,060 $0.3500 -231,600 6,418,400 24 Jun 2025 See footnotes
* indicates a reported price that failed the local validity check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .